Start Free Trial
Pricing
Log In
Log In
Upgrade browser for full Crunchbase experience. You're accessing Crunchbase in a browser that is no longer supported.
Learn More
ImmunityBio Logo
ImmunityBio Growth Score
78
CB Rank
8919
Heat Score
76
ImmunityBio is a late-stage immunotherapy startup that is developing treatments to drive immunogenic pathways in the fight against cancer.
Founded
obfuscation
PublicPost-IPO Equity Culver City, California, United States501-1000 immunitybio.com
Health Care
Health Diagnostics
Oncology
Therapeutics
Overview

ImmunityBio
Total Funding
obfuscation
Growth Score
78
Heat Score
76

Total Funding
obfuscation
obfuscation
Post-IPO Equity raised
obfuscation
Growth Score78
-14 pts
in past quarter
Heat Score 76
-5 pts
in past quarter

Company Performance Metrics

Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Learn More >
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
+4 more milestones
See more interactive data and historical milestones on desktop for the best experience

About ImmunityBio

CB Rank
8919
ImmunityBio is a late-stage immunotherapy startup that is developing treatments to drive immunogenic pathways in the fight against cancer.
Founded
obfuscation
PublicPost-IPO Equity Culver City, California, United States501-1000 immunitybio.com
Health Care
Health Diagnostics
Oncology
Therapeutics

Funding Rounds

Post-IPO Equity
OBF
in
obfuscation
Post-IPO Equity
OBF
in
obfuscation
Post-IPO Equity
OBF
in
obfuscation

Key People

Details

Sub-Organization of 
NantWorks Logo
NantWorks
Legal Name NantBioCell LLC
Also Known As NantCel
Operating Status Active
Stock Symbol  NASDAQ:IBRX
Company Type For Profit
Founders  Patrick Soon-Shiong
About the Company
NantCel is an offshoot of Soon-Shiong's NantWorks conglomerate, developing molecular-level cell-based treatments for diseases. The company discovers and develop immunology based treatments for diseases through cell-based treatments at the molecular level. NantCell was formerly known as NantBioCell. It operates as a subsidiary of NantWorks.
Phone Number +1 844-696-5235
Contact Email info@immunitybio.com
Predictions & Insights

Growth Insight

See this Growth Insight
ImmunityBio is
Lorem
 to be growing
Top Contributing Factors
Recently Raised Funding

Products & Services

ANKTIVA (nogapendekin alfa inbakicept-pmln)
An IL-15 receptor superagonist approved to activate and expand natural killer (NK) and T cells, used to treat BCG-unresponsive non-muscle invasive bladder cancer and reverse lymphopenia in cancer patients.
Cancer BioShield™ Platform
A multi-modal immunotherapy platform combining ANKTIVA, off-the-shelf CAR-NK cells, and memory cytokine-enriched NK cell therapy to restore immune function and combat tumor immune evasion.

Unlock More with Crunchbase Pro
  • Full access to financial & funding data on unlimited profiles
  • Export up to 2k results/month for analysis
  • Track market signals on competitors, products, and R&D
  • Preview private company insights and predictions
Financials

Company Funding

Total Funding Amount 
obfuscation
Number of Funding Rounds 16
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Post-IPO Equity - ImmunityBio Logo
Post-IPO Equity - ImmunityBio
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - ImmunityBio Logo
Post-IPO Equity - ImmunityBio
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - ImmunityBio Logo
Post-IPO Equity - ImmunityBio
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - ImmunityBio Logo
Post-IPO Equity - ImmunityBio
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - ImmunityBio Logo
Post-IPO Equity - ImmunityBio
—
obfuscation
— Post-IPO Equity

Funding Rounds

Total Funding Amount 
obfuscation
Number of Funding Rounds 16
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Post-IPO Equity - ImmunityBio Logo
Post-IPO Equity - ImmunityBio
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - ImmunityBio Logo
Post-IPO Equity - ImmunityBio
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - ImmunityBio Logo
Post-IPO Equity - ImmunityBio
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - ImmunityBio Logo
Post-IPO Equity - ImmunityBio
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - ImmunityBio Logo
Post-IPO Equity - ImmunityBio
—
obfuscation
— Post-IPO Equity

Investors

Investments

Number of Acquisitions 3

Investment Breakdown

Number of Acquisitions 3
Market Intelligence
People
View Profiles & Contacts
Headcount 501-1000 Employee Profiles 11 Contacts 380

Employee Profiles

News

News and Press

News•May 26, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•May 26, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•May 26, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•May 26, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
Access a complete feed of recent news and press, from product launches to leadership changes.
Technology
View Tech Report

Monthly Web Visits

35,561
-7.18%
 in past month

IT Spend

$1.9MThis year, ImmunityBio is projected to spend $1.9M on IT, according to Aberdeen.

Interest Signals

TopicSurge Score
Pipeline Management Logo
Pipeline Management
100
Linux Logo
Linux
100
Time-of-Flight (ToF) 3D Cameras Logo
Time-of-Flight (ToF) 3D Cameras
98

Actively Used Products

18ImmunityBio uses 18 technology products and services including HTML5, Fonts.com, and  Bootstrap, according to G2 Stack.

Active Website Tech Count

41ImmunityBio is actively using 41 technologies for its website, according to BuiltWith. These include Common Crawl, Viewport Meta, and  IPhone / Mobile Compatible.

Total IP

237The intellectual property of ImmunityBio includes 140 registered patents primarily in the 'Medical Or Veterinary Science; Hygiene' category, according to IPqwery. Additionally, ImmunityBio has registered 97 trademarks with the most popular class being 'Pharmaceutical, veterinary and sanitary products', according to IPqwery.
Sub-Organizations
Frequently Asked Questions

Where is ImmunityBio's headquarters? ImmunityBio is located in Culver City, California, United States.Who invested in ImmunityBio? ImmunityBio has 3 investors including Oberland Capital and  Oberland Capital.When was the last funding round for ImmunityBio? ImmunityBio closed its last funding round on
obfuscation
from a Post-IPO Equity round.Who are ImmunityBio's competitors? Alternatives and possible competitors to ImmunityBio may include Aura Biosciences, Calidi Biotherapeutics, and  Canton Strategic Holdings.How much funding has ImmunityBio raised to date? ImmunityBio has raised
obfuscation
.
Who We Are
What We Do
Helpful Links
AI Content may contain mistakes and is not legal, financial or investment advice. Learn more.
Terms of Service | Privacy Policy | Sitemap | © 2026 Crunchbase Inc. All Rights Reserved.
(3237dbc 1)
|